Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top

International Journal of Clinical Oncology

Issue 12/2025

Content (29 Articles)

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer, panitumumab plus sotorasib for colorectal cancer, and vorasidenib for glioma

Noriomi Matsumura, Masaki Mandai

Toward safe clinical deployment of remote robotic surgery in Japan: five-year validation of the hinotori™ system using 5G wireless communication

  • Open Access
  • JSCO Board of Directors Series

Takuto Hara, Yoshifumi Morihiro, Yuki Horise, Shuhei Komatsu, Masanao Ohashi, Hiroaki Kitatsuji, Akihisa Yao, Yoshihiro Muragaki, Hideaki Miyake

Future perspective of clinical usefulness of metabolic and mitochondrial heterogeneity in triple-negative breast cancers

Jing Li, Ravi Velaga, Yuko Takano, Norikazu Masuda

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer

Yusuke Kinugasa, Kay Uehara, Kensei Yamaguchi, Yutaka Saito, Keiko Murofushi, Tamotsu Sugai, Megumi Ishiguro, Soichiro Ishihara, Hideki Ueno, Shiro Oka, Takeshi Kato, Yukihide Kanemitsu, Hisato Kawakami, Hirotoshi Kobayashi, Yoshihiro Sakamoto, Manabu Shiozawa, Akio Shiomi, Eiji Shinozaki, Hirotoshi Takiyama, Hiroya Taniguchi, Takako Eguchi Nakajima, Kinichi Hotta, Keiji Matsuda, Kohei Murata, Satoshi Morita, Kentaro Yamazaki, Masahiro Yoshida, Naohiko Yamaguchi, Hiroyasu Kagawa, Shinichi Yamauchi, Yoichi Ajioka

Real-world adherence to antiemetic guidelines in Japanese patients receiving high or carboplatin-based moderate emetic risk chemotherapy

Ayako Okuyama, Takahiro Higashi, Masakazu Abe, Toshinobu Hayashi, Hirotoshi Iihara, Keiko Iino, Chihiro Ishii, Kenji Okita, Makoto Wada, Nobuyuki Yamamoto, Sadamoto Zenda, Kenjiro Aogi, Eriko Satomi

Chemotherapy-related hand–foot syndrome and hand–foot skin reaction: a review of management and possible approaches for Asian patients by the Japanese pharmacist-led oncodermatology study team

Yohei Iimura, Hirotoshi Iihara, Yoshitaka Saito, Hisanaga Nomura, Takuya Iwamoto, Mayumi Kotera, Yusuke Tsuchiya, Tatsuya Sumiya, Mariko Kono, Daisuke Hirate, Tomohiro Kurokawa, Toshinobu Hayashi, Hironobu Hashimoto, Junichi Higuchi, Ryuta Urakawa, Hiroyuki Saotome, Seiichiro Kuroda

The role of hypoxia-inducible factor-1α on colon cancer progression and metastasis

Mohamed J. Saadh, Mareb Hamed Ahmed, Rafid Jihad Albadr, Gaurav Sanghvi, R. Roopashree, Aditya Kashyap, A. Sabarivani, Jasur Rizaev, Waam Mohammed Taher, Mariem Alwan, Mahmod Jasem Jawad, Ali M. Ali Al-Nuaimi

Evaluation of factors associated with clinically problematic hiccups in cisplatin-containing treatment with dexamethasone and neurokinin 1 receptor antagonists

Yoshitaka Saito, Yoh Takekuma, Jun Sakakibara-Konishi, Yasushi Shimizu, Ichiro Kinoshita, Mitsuru Sugawara

Physical activity and risk of thyroid cancer: a systematic review and meta-analysis of prospective cohort studies

Heram Cho, Yunseo Park, Seung-Kwon Myung

Lung immune prognostic index as a biomarker for predicting the benefit of immune checkpoint inhibitor plus chemotherapy in older patients with non-small cell lung cancer: a secondary analysis of the NEJ057 study

Takehiro Tozuka, Yoko Tsukita, Kohei Kushiro, Shinobu Hosokawa, Hitomi Nogawa, Satoshi Arai, Sayo Soda, Daisuke Arai, Kei Takamura, Ryoichi Honda, Kosuke Hamai, Yukiko Namba, Yasutaka Kawai, Takashi Kikuchi, Kensuke Nakazawa, Takayuki Honda, Noriyuki Ebi, Yutaka Yamada, Tomonori Makiguchi, Masahiro Seike, Satoshi Morita, Kunihiko Kobayashi, Hajime Asahina

Anti-HER2 plus endocrine therapy versus anti-HER2 plus chemotherapy in hormone receptor-positive and HER2-positive metastatic breast cancer: a retrospective study

Zhenhua Fan, Yang Yuan, Xiaoyan Chen, Tao Wang, Shaohua Zhang, Li Bian, Xueli Mo

Risk of severe infections in patients with triple-negative breast cancer treated with atezolizumab plus nab-paclitaxel: a real-world, postmarketing database study in Japan

Akinori Yuri, Sayuri Nakane, Yuki Miyano, Kana Yamada, Hiroshi Sugano, Erika Nakatsuji, Masahiko Aoki, Ayako Murayama

Lymph node metastasis risk in submucosal invasive gastric cancer based on C-reactive protein gene polymorphism analysis

Kotaro Honda, Kohei Taniguchi, Kazumasa Komura, Tomohito Tanaka, Hidero Yoshimoto, Kentaro Matsuo, Yoshiro Imai, Ryo Tanaka, Mitsuaki Ishida, Yoshinobu Hirose, Satoru Motoyama, Sang-Woong Lee

FLOT vs DOS neoadjuvant chemotherapy in locally advanced gastric cancer: propensity score analysis

Lu-yang Zhang, Sen Zhang, Xuan Zhao, Hao Li, Lu Zang, Jun-jun Ma, Min-hua Zheng, Abe Fingerhut

Outcomes of additional chemotherapy for esophageal squamous cell carcinoma following non-curative endoscopic submucosal dissection

Yujiro Adachi, Yoshito Hayashi, Shinji Yoneda, Ayaka Tajiri, Hiromu Fukuda, Eiji Kimura, Kentaro Nakagawa, Hirotsugu Saiki, Ryotaro Uema, Takeo Yoshihara, Yoshiki Tsujii, Tetsuo Takehara

Site-specific prevalence of the NFE2L2 mutation in esophageal squamous cell carcinoma

Akihiko Chida, Hideyuki Hayashi, Norihito Ishida, Eiichiro So, Shotaro Kishimoto, Sara Horie, Kai Tsugaru, Satoru Matsuda, Hirofumi Kawakubo, Hiroshi Nishihara, Yasuo Hamamoto, Takanori Kanai, Yuko Kitagawa, Kenro Hirata

Elevated proportion of eosinophils predicts immune-related adverse events and improved survival in patients with gastric cancer treated with nivolumab

Sohei Matsumoto, Hiroshi Nakade, Tomohiro Kunishige, Shintaro Miyao, Satoko Aoki, Akinori Tsujimoto, Takanari Tatsumi, Masahiro Soga, Masayuki Sho

Characterization of the mutational landscapes in Japanese patients with early-onset colorectal cancer from comprehensive genomic profiling data

Yutaka Okagawa, Tomohiro Kubo, Shin Ariga, Norito Suzuki, Hiroki Tanabe, Susumu Sogabe, Atsushi Ishiguro, Tatsuru Ikeda, Shinya Minami, Masahiro Hirakawa, Ichiro Kinoshita, Kohichi Takada

Prognostic implications of morphological subtypes in a surgical cohort of perihilar cholangiocarcinoma: the overriding impact of nodal status

Poowanai Sarkhampee, Weeris Ouransatien, Satsawat Chansitthichok, Nithi Lertsawatvicha, Paiwan Wattanarath

Efficacy and safety of FOLFOX for Japanese patients with advanced biliary tract cancer as second-line or later chemotherapy (JON2107-B study)

Takeshi Terashima, Chigusa Morizane, Akihiko Chida, Akiko Todaka, Kumiko Umemoto, Yujiro Kawakami, Tatsuya Yamashita, Makoto Ueno, Junji Furuse, Hiroaki Nagano

Plasma CAF22 and NfL reflect neuromuscular decline during cisplatin-based chemotherapy and radical cystectomy in muscle-invasive bladder cancer

Rizwan Qaisar, Shah Hussain, Firdos Ahmad, Asima Karim

Cross-resistance among novel androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer

Takuya Oishi, Naoki Fujita, Yohei Kawashima, Masanao Shinohara, Ryuji Tabata, Fumiya Yoneyama, Ryuma Tanaka, Hikari Miura, Kyo Togashi, Kazutaka Okita, Hirotaka Horiguchi, Toshikazu Tanaka, Daisuke Noro, Yuichiro Suzuki, Satoshi Sato, Chikara Ohyama, Shingo Hatakeyama

Stage IA and IC adult granulosa cell tumors: Clinical features, long-term outcomes and prognostic factors in a 333-patient cohort over three decades

Jingwen Gan, Xiao Ma, Ying Cao, Dongyan Cao, Huimei Zhou, Mei Yu, Tao Wang

Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy

Adriana Ionelia Apostol, Matteo Bruno, Carolina Maria Sassu, Serena Maria Boccia, Laura Vertechy, Giorgia Russo, Ilary Ruscito, Filippo Maria Capomacchia, Giovanni Scambia, Anna Fagotti, Claudia Marchetti

Factors in oncologists’ attitudes on do-not-attempt-resuscitation orders for patients with cancer

Midori Kadowaki, Chikako Shimizu, Shimon Tashiro, Yoko Takada, Tsunakuni Ikka

Comment on: “Comparative neurological safety of novel hormonal therapies in advanced prostate cancer: a Bayesian network meta-analysis of randomized trials”

Yuekun Fang, Shengyi Chen, Bin Cheng

Comment on: significance of preoperative mean corpuscular volume in patients with stage II/III colorectal cancer and anemia

Min Zou, Yansheng Zhang, Feng Gao, Zengqiang Yang

Critical evaluation of cross-resistance among novel androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer by Oishi et al

Marhaba Khan, Laiba Riaz

List of reviewers 2024–2025

  • Acknowledgments

Nov 25
Issue: 11/2025
Jan 26
Issue: 1/2026

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Case simulations: Biomarker-driven management of NSCLC (Link opens in a new window)

Do you want to assess your biomarker testing skills and management decisions? Use these simulation-based case studies based on realistic NSCLC scenarios to do so in a practical and secure environment.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
COMMISSIONED

How-to guide for healthcare professionals: understanding genomic reports

This educational activity was initiated, funded and co-developed by Boehringer Ingelheim and is intended for healthcare professionals in the UK and Ireland only. 

Genomic testing helps inform cancer diagnosis, prognosis, and treatment. A genomic report is generated by the laboratory carrying out next-generation sequencing to analyze biopsy samples. Access this educational microsite to learn more about typical genomic report content and how to interpret test results for patients with cancer.

NP-GB-106631 | Jan 2026

Commissioned by:
  • Boehringer Ingelheim
Learn more
Image Credits
Biomarker-driven management of NSCLC logo/© Springer Health+ IME, DNA double helix structure on a purple background/© 2025 Adobe